These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17848298)

  • 1. Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins.
    Rischin D; Fisher R; Peters L; Corry J; Hicks R
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S61-3. PubMed ID: 17848298
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond detection: novel applications for PET imaging to guide cancer therapy.
    Rajendran JG; Mankoff DA
    J Nucl Med; 2007 Jun; 48(6):855-6. PubMed ID: 17536105
    [No Abstract]   [Full Text] [Related]  

  • 3. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.
    Hicks RJ; Rischin D; Fisher R; Binns D; Scott AM; Peters LJ
    Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1384-91. PubMed ID: 16133382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
    Rischin D; Hicks RJ; Fisher R; Binns D; Corry J; Porceddu S; Peters LJ;
    J Clin Oncol; 2006 May; 24(13):2098-104. PubMed ID: 16648512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.
    Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The end of the hypoxic EPOch.
    Aguilera TA; Giaccia AJ
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):895-7. PubMed ID: 25832683
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy of FDG-PET in head-and-neck cancer with neck metastasis after definitive radiation treatment: in regard to Yao et al. (Int J Radiat Oncol Biol Phys 2005;63:991-999).
    Wang TF; Tsai EL; Kao RH
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):633; author reply 633-4. PubMed ID: 16690448
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer.
    Eschmann SM; Paulsen F; Bedeshem C; Machulla HJ; Hehr T; Bamberg M; Bares R
    Radiother Oncol; 2007 Jun; 83(3):406-10. PubMed ID: 17543402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome: in regard to Evans et al. (Int J Radiat Oncol Biol Phys 2007;69:1024-1031).
    Bussink J; van der Kogel AJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1616. PubMed ID: 18374238
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effectiveness of the radiosensitizer cisplatin. A pilot study].
    Klima A; Szepesi S
    Laryngol Rhinol Otol (Stuttg); 1987 Sep; 66(9):457-9. PubMed ID: 3683038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia in head and neck cancer.
    Isa AY; Ward TH; West CM; Slevin NJ; Homer JJ
    Br J Radiol; 2006 Oct; 79(946):791-8. PubMed ID: 16854964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
    Menda Y; Graham MM
    Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
    Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxic Cell Radiosensitization in Head and Neck Squamous Cell Carcinoma: Running Out of Air.
    Morse RT; Mell LK
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):783-785. PubMed ID: 38851276
    [No Abstract]   [Full Text] [Related]  

  • 16. Can post-RT FDG PET accurately predict the pathologic status in neck dissection after radiation for locally advanced head and neck cancer? In regard to Rogers et al. (Int J Radiat Oncol Biol Phys 2004;58:694-697).
    Yao M; Buatti JM; Dornfeld KJ; Graham MM; Smith RB; Funk GF; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):306-7; author reply 307. PubMed ID: 15629631
    [No Abstract]   [Full Text] [Related]  

  • 17. A clinical study to assess chlorpromazine as hypoxic cell sensitizer in head & neck cancer treated with conventional radiation.
    Huilgol NG; Chatterjee N; Singh BB
    Indian J Cancer; 1998 Sep; 35(3):97-100. PubMed ID: 10226398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
    Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
    Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
    Vordermark D; Brown JM
    Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.